Drugs / GEN1056
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05586321 | Oct 2022 → Oct 2025 | cancer | Genmab | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1056 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05586321 ↗ |
| Route | Intravenous | “GEN1056 will be administered as an intravenous (IV) infusion.” NCT05586321 ↗ |